ClinicalTrials.gg
TerminatedNCT07052682Updated Aug 19, 2025Results posted

A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

A Phase 1 interventional study of Ontamalimab in Steatohepatitis, sponsored by Takeda. Terminated at 15 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

Why this study was terminated
Study was terminated early by the sponsor due to a strategic shift and reprioritization of clinical programs within Takeda.

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Jan 2023, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 211 studies in Fatty Liver with a site in United States — 41 open to participants now, 47 under way, 8 of them phase 3. Fatty Liver · United States.

Enrollment
140th of 162
11 · median 45
Started
2023
with 8 others
Phase 1
18 of 211
3 open now
Registered
191st of 211
by date

Among the 211 studies in Fatty Liver with a site in United States, this one is the 140th largest by enrollment of the 162 interventional ones that give a count, is one of 9 that started in 2023, is one of 18 in phase 1, and was the 191st registered.

Fatty Liver

663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

41 of the 211 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 211 studies in Fatty Liver with a site in United States, or all of them as a file.
02

Study summary

The main aim of this study is to evaluate the safety and tolerability of ontamalimab in participants with a liver disease called nonalcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH) with scarring in the liver (fibrosis stage 1 to 4). The study will also check if there are any important changes in the body's health markers (biomarkers) from the beginning of the study to see if ontamalimab stops liver scarring and reduces inflammation of the liver.

Participants will be in the study for approximately up to 46 weeks.

03

Conditions studied

  • Steatohepatitis

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant is willing and able to understand and fully comply with study procedures and requirements, in the opinion of the investigator.
  2. The participant and/or the participant's legally acceptable representative has provided (that is, in writing, documented via a signed and dated informed consent form [ICF] or electronic consent [eConsent] if applicable) and any required privacy authorization prior to the initiation of any study procedures.
  3. The participant is aged 18 to 70 years, inclusive, at the time of signing the ICF.
  4. The participant has signs of fibrogenic activity (Pro-C3 greater than or equal to [>=] 12.6 nanograms per milliliter [ng/mL], ELF score >=7.7) at the Week -8 (screening visit 1 [SV1]) (applies to all participants regardless of whether historical results are available at screening).
  5. The participant has indication of NASH via biopsy (Nonalcoholic fatty liver disease activity score [NAS] >=3 with at least 1 point in lobular inflammation) and liver fibrosis stage 1 (F1) through fibrosis stage 4 compensated cirrhotic (F4cc) according to NASH Clinical Research Network (CRN).
  6. The participant is a male participant or a nonpregnant, nonlactating female participant who, if sexually active, agrees to comply with the requirements of the protocol, or a female participant of nonchildbearing potential. Participants of who are sexually active must agree to use appropriate contraception (that is, highly effective methods for female participants and medically appropriate methods for male participants) for the duration of the study and for at least 12 weeks after the last dose of study drug.
  7. The participant, if capable of breastfeeding, agrees to forego breastfeeding for the period from informed consent until 12 weeks after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. The following laboratory findings are exclusionary for all participants if found during screening visits (Week -8 [SV1], Week -6 [SV2] or at Day -4 visit [Visit 4a2]):

    1. (AST) levels greater than (>) 5*the (ULN).
    2. Alanine aminotransferase (ALT) levels >5*ULN.
  2. The following laboratory findings are exclusionary for all participants if found during either screening visit (SV1 or SV2):

    1. Alkaline phosphatase (ALP) >=2*ULN.
    2. Serum creatinine >=1.5*ULN or has an estimated (eGFR) less than (\<) 45 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2).
    3. (INR) >=1.3 (except for participants who are receiving anticoagulant treatment).
    4. Total level (TBL) >=ULN (except for participants with a documented history of Gilbert's syndrome if direct bilirubin is within normal reference range).
    5. Direct bilirubin >=3*ULN.
    6. count \<60*10\^9 per liter (/L).
  3. The participant has been diagnosed with decompensated liver disease, or has new signs of decompensation and/or change in disease status based on the judgment of the investigator (including but not limited to clinically significant changes in TBL, albumin, INR, creatinine, and/or AST and ALT levels) are observed during the screening period, or has any of the following during screening period:

    1. Presence or history of ascites, hepatic encephalopathy, or variceal bleeding.
    2. Presence or history of >6 (Class B or C), unless due to therapeutic anticoagulation.
    3. Presence or history of model for end-stage liver disease (MELD) score >12. Note: It is the investigator's decision, in consultation with the sponsor, to allow participants to enter the study who have clinically meaningful rising tendencies in liver chemistries or significantly elevated liver chemistries that do not yet satisfy Exclusion Criterion #1 but could be interpreted as clinically concerning (that is, AST or ALT >4*ULN) at any visit during the screening period.
  4. The participant has other diagnosed causes of liver disease based on medical history and/or baseline evaluation of laboratory and/or histology results, including, but not limited to viral (example, chronic , hepatitis B virus surface antigen [HBsAg] positive, or hepatitis B core antibody [HBcAB] positive; or chronic or hepatitis C virus antibody [HCVAb] positive and hepatitis C [HCV] ribonucleic acid [RNA] positive; or [HIV]-antibody positive), alcoholic (alcohol consumption greater than 4 units on any day or 14 units per week for male participants, or greater than 3 units on any day or 7 units per week for female participants [1 unit of alcohol is present in one 12 ounces [oz]/355 milliliters [mL] beer (approximately 5 percentage [%] alcohol), one 5 oz/148 mL glass of wine (approximately 12% alcohol), and one 1.5 oz/44 mL measure of 80-proof liquor (approximately 40% alcohol)]), or conditions (example, primary sclerosing cholangitis, primary biliary cirrhosis, autoimmune hepatitis, drug-induced hepatotoxicity), and other rare liver disease (example, alpha-1-antitrypsin deficiency, Wilson disease, hemochromatosis). Note: If a participant tests negative for HBsAg but positive for HBcAb, the participant would be considered eligible if no presence of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) is confirmed by HBV DNA polymerase chain reaction (PCR) reflex testing performed by the central laboratory. Participants who are HCVAb positive without evidence of HCV RNA may be considered eligible (spontaneous viral clearance or previously treated and cured [defined as no evidence of HCV RNA at least 12 weeks before baseline]).
  5. The participant has a history of impaired hemostasis that, in the investigator's judgement, would increase the risk to the participant if he or she participates in the study.
  6. The participant has a significant concurrent medical condition at the time of screening or baseline, including, but not limited to, the following:

    1. Any major illness/condition or evidence of an unstable clinical condition (example, hepatic, renal, hematologic, gastrointestinal, endocrine [example, uncontrolled diabetes or type 1 diabetes mellitus, or thyroid disease], neurological [pre-existing demyelinating disorder such as multiple sclerosis or new onset seizures, unexplained sensory motor, or cognitive behavioral, neurological deficits, or significant abnormalities noted during screening], cardiovascular, pulmonary, immunologic [example, Felty's syndrome], or local active infection/infectious illness [any bacterial, fungal, or viral, example, clinically active cytomegalovirus, Epstein-Barr virus, herpes simplex virus]) that, in the investigator's judgment will substantially increase the risk to the participant if he or she participates in the study.

      Note: Participants with (HbA1c) of >=6.5% at screening (SV1; Week -8) without a previous diagnosis of type 2 diabetes mellitus (T2DM) should be excluded from the study. Participants with a previous diagnosis for T2DM are permitted to enter the study if on a stable regimen of antidiabetic therapy for at least 90 days before screening. Participants who are on a stable regimen of antidiabetic therapy for at least 90 days before screening (SV1; Week -8) and have HbA1c of >=9% at Week -8 (SV1) should be excluded.

    2. Presence of acute coronary syndrome (example, acute myocardial infarction, unstable angina pectoris) within 24 weeks before screening.
    3. History of significant cerebrovascular disease within 24 weeks before screening.
    4. Cancer or history of cancer, including hepatocellular carcinoma or cholangiocarcinoma, or lymphoproliferative disease within the previous 5 years (other than resected cutaneous basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix that has been treated with no evidence of recurrence).
    5. Any other severe acute or chronic medical or psychiatric condition or laboratory or abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
    6. Transplanted organ or history of liver transplantation.
    7. Significant trauma or major surgery within 4 weeks before the first screening visit, or with any major elective surgery planned to occur during the study.
  7. The participant has severe active inflammatory bowel disease (IBD). Participants with inactive IBD or active of mild to moderate severity that was documented either by prior endoscopy or in previous medical records for >6 months are permitted to enter if they do not require biological treatment or Janus kinase (JAK) inhibitors. Treatment with leukocyte apheresis or selective lymphocyte, monocyte, or granulocyte apheresis or plasma exchange 30 days before baseline (Day 1).
  8. The participant has a severe immune-mediated inflammatory disease (IMID) (example, rheumatoid arthritis, spondylarthritis disease spectrum, connective tissue disorders, cutaneous inflammatory conditions such as psoriasis, atopic dermatitis, hidradenitis suppurativa, asthma, multiple sclerosis). Participants with inactive IMID or active IMID of mild to moderate severity are permitted to enter the study.
  9. The participant has a change in body weight >=5% three months before start of the screening or after qualifying liver . If the participant had a liver biopsy within 24 weeks of screening but experienced a weight change of >=5% since the date of liver biopsy, the liver biopsy must be repeated at screening.
  10. The participant has any laboratory abnormality or condition that, in the investigator's opinion, could adversely affect the safety of the participant or impair the assessment of study results.
  11. The participant has known to ontamalimab or formulation .
  12. The participant has active or latent infection with mycobacterium tuberculosis (TB) who have not completed a generally accepted full course of treatment before screening.
  13. The participant has clinically significant abnormal chest X-ray findings at SV1 (or up to 12 weeks before the first screening visit if available), such as presence of active TB, general infections, heart failure, or .
  14. The participant has a positive interferon-gamma release assay (IGRA) at screening or within 12 weeks before screening even in the absence of previously diagnosed active or latent TB. IGRA screening may be repeated during the screening period if the initial result is indeterminate. The participant may be enrolled if confirmatory IGRA results from the central laboratory are negative. If the confirmatory IGRA results from the central laboratory are positive, the participant should be screen-failed. If both initial and confirmatory IGRA results are indeterminate, the participant may be enrolled after a Mantoux tuberculin skin test is negative and after consultation with the sponsor and a pulmonary or infectious disease specialist who determines low risk of infection (example, the participant would be acceptable for [example, anti-tumor necrosis factor (TNF) treatment] without additional action). If the time for consultation exceeds the visit window, the participant should be screen-failed and can be rescreened after the consultation establishes eligibility for study participation. This consultation must be included in the participant's medical history.
  15. The participant has any unexplained symptoms suggestive of progressive multifocal leukoencephalopathy (PML) based on the targeted neurological assessment during the screening period.
  16. The participant has HIV.
  17. The participant has a medical condition (example, morbid obesity, claustrophobia) that prevent execution of protocol procedures including percutaneous liver biopsy, liver stiffness measurement (LSM) by FibroScan, and magnetic resonance imaging (MRI).
  18. The participant is receiving treatment with vitamin E, thiazolidinediones, or glucagon-like peptide-1 receptor agonists (GLP-1 RA) unless on a stable dose for 3 months before qualifying liver biopsy and not initiated after qualifying liver biopsy and is anticipated to maintain the same dosing regimen throughout study participation.
  19. The participant is using drugs, herbs, or supplements historically associated with causing or worsening nonalcoholic fatty liver disease (NAFLD)/NASH within 24 weeks before qualifying liver biopsy or any time after qualifying liver biopsy is performed, including the use of total parenteral nutrition.
  20. The participant has a positive urine screen for amphetamines, cocaine, or opioids related to the use of these drugs at screening.
  21. The participant is receiving methadone or buprenorphine unless on stable maintenance treatment for at least 6 months before screening. Participants with a positive urine drug screen due to prescription opioid-based medication are eligible if the prescription and diagnosis are reviewed and approved by the investigator.
  22. The participant is using any prohibited concomitant medications as described in the protocol.
  23. The participant has received a live (attenuated) vaccine within 4 weeks before baseline or is anticipated to receive a during the study.
  24. The participant has participated in another study of a drug or device within 30 days before or within 5 half-lives of the prior investigational agent (whichever is longer) before baseline (Day 1).
  25. The participant has participated in another investigational study targeting NASH, type 2 diabetes mellitus, or obesity within 6 months before baseline (Day 1).
  26. The participant is concurrently participating in another therapeutic clinical study.
  27. The participant has previously received ontamalimab.
  28. The participant has had previous exposure to anti-integrin or anti-adhesion molecule treatment example, natalizumab, efalizumab, etrolizumab, vedolizumab, or any other investigational anti-integrin/adhesion molecule within 90 days before baseline (Day 1).
  29. The participant has had previous exposure to any other biologic drugs with immunomodulatory properties such as anti-TNF, including biosimilars or anti-interleukin (IL)-12/23, or any nonbiologic treatment with immunomodulatory properties such as JAK inhibitors within 90 days or 5 half-lives (whichever is longer) before baseline (Day 1).
  30. The participant is unavailable for follow-up assessment or investigator concern for participant's compliance with the protocol procedures.
  31. The participant is a study site employee, an immediate family member (example, spouse, parent, child, sibling), or is in a dependent relationship with a study site employee who is involved in conduct of this study or may consent under duress.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Ontamalimab

    Participants receive ontamalimab 75 milligrams (mg) subcutaneous (SC) injection using a prefilled syringe once every 4 weeks (Q4W) on Day 1 and the last dose is administered at Week 20 with a total treatment period of 24 weeks.

    Drug: Ontamalimab

Interventions

  • Ontamalimab SC injection.

    Also known as: SHP647, PF-00547659, TAK-647

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs was defined as any event that emerged or manifested at or after the initiation of treatment with a study drug or medicinal product, or any existing event that worsened in either intensity or frequency following exposure to the study drug or medicinal product.

    Time frame: From first dose of study drug up to Week 36

  2. Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values

    Laboratory parameters included serum chemistry, hematology, urinalysis, and coagulation. Any Abnormality in clinical laboratory results which are deemed clinically significant by the investigator were reported.

    Time frame: From first dose of study drug up to Week 36

  3. Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECGs) Findings

    ECG included heart rate, QRS intervals, QT intervals, PR intervals, RR intervals and QT intervals corrected for heart rate using Fridericia's formula (QTcF) intervals parameters measurement. Any abnormality in ECG assessments which were deemed clinically significant by the investigator were reported.

    Time frame: From first dose of study drug up to Week 24

  4. Number of Participants With Clinically Significant Abnormalities in Vital Signs

    Vital signs included measurement of pulse rate, systolic, diastolic blood pressure, respiratory rate, Body mass index (BMI), body temperature and height. Any abnormality in vital signs which are deemed clinically significant by the investigator were reported.

    Time frame: From first dose of study drug up to 36 weeks

  5. Number of Participants With Clinically Significant Abnormalities in Body Weight

    Body weight was measured in kilograms (kg) at the specified time points. Any abnormality in body weight which are deemed clinically significant by the investigator were reported.

    Time frame: From first dose of study drug up to Week 36

Secondary outcomes

  1. Percent Change From Baseline in Pro-Collagen Type III (Pro-C3) Through Week 24

    Researchers measured the change in liver scarring using biomarkers. Biomarkers are substances measured in blood that show normal or abnormal activity taking place in the liver. Pro-C3 was measured in serum; Increasing levels indicate worsening of fibrosis activity. Blood samples were collected for assessment of Pro-C3 biomarker.

    Time frame: Baseline up to Week 24

  2. Percent Change From Baseline in Enhanced Liver Fibrosis (ELF) Through Week 24

    Researchers measured the change in liver scarring using biomarkers. Biomarkers are substances measured in blood that show normal or abnormal activity taking place in the liver. Blood samples were collected for an assessment of ELF score. The ELF score was calculated from the concentrations of the following serum biomarkers: tissue inhibitor of metalloproteinases- 1 (TIMP-1), procollagen III n-terminal propeptide (PIIINP), and hyaluronic acid (HA). ELF was a score on a scale of severity assessment against biopsy-proven fibrosis. A score of less than (\<) 7.7 is none to mild, greater than (\>) 7.7-9.8 is moderate, \>9.8 is severe. Higher ELF scores represented worse disease outcome.

    Time frame: Baseline up to Week 24

  3. Change From Baseline in Liver Iron-corrected T1 Mapping by Magnetic Resonance Imaging (cT1 MRI) at Week 24

    cT1 is a quantitative MRI relaxation parameter that measures liver inflammation and fibrosis. Participants underwent abdominal MRI to obtain liver cT1, which were used to assess fibro-inflammation. The change from baseline was calculated by subtracting the baseline values from the individual post-baseline values.

    Time frame: Baseline, Week 24

07

Results

Posted Aug 19, 2025
Limitations and caveats
The study was terminated early by the sponsor due to a strategic shift and reprioritization of clinical programs within Takeda.

Participant flow

Participants took part in the study at 20 investigative sites in the United States from 18 January 2023 to 30 December 2024.

Participant flow — Overall Study
MilestoneOntamalimab
Started11
Completed7
Not completed4
Withdrew: Withdrawal by subject4

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs was defined as any event that emerged or manifested at or after the initiation of treatment with a study drug or medicinal product, or any existing event that worsened in either intensity or frequency following exposure to the study drug or medicinal product.

Time frame:
From first dose of study drug up to Week 36
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsOntamalimab
Number of Participants With Treatment-emergent Adverse Events (TEAEs)6
PrimaryNumber of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values

Laboratory parameters included serum chemistry, hematology, urinalysis, and coagulation. Any Abnormality in clinical laboratory results which are deemed clinically significant by the investigator were reported.

Time frame:
From first dose of study drug up to Week 36
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values
ParticipantsOntamalimab
Serum Chemistry0
Hematology0
Urinalysis0
Coagulation0
PrimaryNumber of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECGs) Findings

ECG included heart rate, QRS intervals, QT intervals, PR intervals, RR intervals and QT intervals corrected for heart rate using Fridericia's formula (QTcF) intervals parameters measurement. Any abnormality in ECG assessments which were deemed clinically significant by the investigator were reported.

Time frame:
From first dose of study drug up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECGs) Findings
ParticipantsOntamalimab
Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECGs) Findings0
PrimaryNumber of Participants With Clinically Significant Abnormalities in Vital Signs

Vital signs included measurement of pulse rate, systolic, diastolic blood pressure, respiratory rate, Body mass index (BMI), body temperature and height. Any abnormality in vital signs which are deemed clinically significant by the investigator were reported.

Time frame:
From first dose of study drug up to 36 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Vital Signs
ParticipantsOntamalimab
Number of Participants With Clinically Significant Abnormalities in Vital Signs0
PrimaryNumber of Participants With Clinically Significant Abnormalities in Body Weight

Body weight was measured in kilograms (kg) at the specified time points. Any abnormality in body weight which are deemed clinically significant by the investigator were reported.

Time frame:
From first dose of study drug up to Week 36
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Body Weight
ParticipantsOntamalimab
Number of Participants With Clinically Significant Abnormalities in Body Weight0
SecondaryPercent Change From Baseline in Pro-Collagen Type III (Pro-C3) Through Week 24

Researchers measured the change in liver scarring using biomarkers. Biomarkers are substances measured in blood that show normal or abnormal activity taking place in the liver. Pro-C3 was measured in serum; Increasing levels indicate worsening of fibrosis activity. Blood samples were collected for assessment of Pro-C3 biomarker.

Time frame:
Baseline up to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Pro-Collagen Type III (Pro-C3) Through Week 24
percent changeOntamalimab
Percent Change From Baseline in Pro-Collagen Type III (Pro-C3) Through Week 24-11.88 (-26.13 to 2.37)
SecondaryPercent Change From Baseline in Enhanced Liver Fibrosis (ELF) Through Week 24

Researchers measured the change in liver scarring using biomarkers. Biomarkers are substances measured in blood that show normal or abnormal activity taking place in the liver. Blood samples were collected for an assessment of ELF score. The ELF score was calculated from the concentrations of the following serum biomarkers: tissue inhibitor of metalloproteinases- 1 (TIMP-1), procollagen III n-terminal propeptide (PIIINP), and hyaluronic acid (HA). ELF was a score on a scale of severity assessment against biopsy-proven fibrosis. A score of less than (\<) 7.7 is none to mild, greater than (\>) 7.7-9.8 is moderate, \>9.8 is severe. Higher ELF scores represented worse disease outcome.

Time frame:
Baseline up to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Enhanced Liver Fibrosis (ELF) Through Week 24
percent changeOntamalimab
Percent Change From Baseline in Enhanced Liver Fibrosis (ELF) Through Week 24-0.13 (-3.61 to 3.35)
SecondaryChange From Baseline in Liver Iron-corrected T1 Mapping by Magnetic Resonance Imaging (cT1 MRI) at Week 24

cT1 is a quantitative MRI relaxation parameter that measures liver inflammation and fibrosis. Participants underwent abdominal MRI to obtain liver cT1, which were used to assess fibro-inflammation. The change from baseline was calculated by subtracting the baseline values from the individual post-baseline values.

Time frame:
Baseline, Week 24
Reported as:
Mean · millisecond (ms)
Change From Baseline in Liver Iron-corrected T1 Mapping by Magnetic Resonance Imaging (cT1 MRI) at Week 24
millisecond (ms)Ontamalimab
Change From Baseline in Liver Iron-corrected T1 Mapping by Magnetic Resonance Imaging (cT1 MRI) at Week 24-32.0 ± 39.77

Adverse events

Collected over From first dose of study drug up to Week 36. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ontamalimab0/11 (0%)0/11 (0%)6/11 (54.5%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventOntamalimab
Hot flushVascular disorders2/11
Abdominal pain upperGastrointestinal disorders1/11
ArthralgiaMusculoskeletal and connective tissue disorders1/11
Decreased appetiteMetabolism and nutrition disorders1/11
DizzinessNervous system disorders1/11
Gastrooesophageal reflux diseaseGastrointestinal disorders1/11
HeadacheNervous system disorders1/11
HypertensionVascular disorders1/11
HypoglycaemiaMetabolism and nutrition disorders1/11
MyalgiaMusculoskeletal and connective tissue disorders1/11

Baseline characteristics

The safety analysis set consisted of all participants who were enrolled in the study and had received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Ontamalimab
Mean49.3 ± 7.03
Sex: Female, Male
Sex: Female, Male(Participants)Ontamalimab
Female7
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ontamalimab
Hispanic or Latino4
Not Hispanic or Latino7
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ontamalimab
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White10
More than one race0
Unknown or Not Reported0
08

Study locations

15 sites
  • Arizona Liver Health
    Chandler, Arizona 85224, United States
  • Adobe Clinical Research, LLC
    Tucson, Arizona 85712, United States
  • Southern California Research Center
    Coronado, California 92118, United States
  • University of California, San Diego, NAFLD Research Center
    La Jolla, California 92037, United States
  • California Liver Research Institute
    Pasadena, California 91105, United States
  • Inland Empire Clinical Trials, LLC
    Rialto, California 92377, United States
  • Covenant Metabolic Specialist LLC
    Fort Myers, Florida 33912, United States
  • Covenant Metabolic Specialist LLC
    Sarasota, Florida 34240, United States
  • Tandem Clinical Research GI, LLC
    Marrero, Louisiana 70072, United States
  • Lucas Research, Inc
    Morehead City, North Carolina 28557, United States
  • The Liver Institute at Methodist Dallas Medical Center
    Dallas, Texas 75203, United States
  • Houston Research Institute
    Houston, Texas 77079, United States
  • Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research LLC
    San Antonio, Texas 78229, United States
  • VCU Dept of Internal Medicine, Division of GI, Hepatology & Nutrition
    Richmond, Virginia 23298, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, …)

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Dec 2024, 23 months.

Results were first posted in Aug 2025, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2025
First posted
Jul 6, 2025
StartActual
Jan 18, 2023
Primary completionActual
Dec 30, 2024
CompletionActual
Dec 30, 2024
Results first posted
Aug 19, 2025
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07052682
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 6, 2025
Start date
Jan 18, 2023
Primary completion
Dec 30, 2024
Completion
Dec 30, 2024
Results posted
Aug 19, 2025
Last update
Aug 19, 2025

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ontamalimab

Start the discussion